title: Attained adult height after childhood asthma: effect of glucocorticoid therapy.
abstract: BACKGROUND
  Although oral and inhaled glucocorticoid therapy may impair growth in children with asthma, the effect of glucocorticoid therapy and asthma on attained adult height has not been extensively studied in representative children in the community.
  
  
  OBJECTIVE
  The study was designed to compare the attained adult height of children with asthma with the attained adult height of nonasthmatic children and to compare the attained adult height of asthmatic children treated with glucocorticoids with the attained adult height of asthmatic children who did not receive glucocorticoids.
  
  
  METHODS
  Residents of Rochester, Minnesota, with onset of asthma from 1964 to 1987 and age- and sex-matched non-asthmatic residents of Rochester were studied. Glucocorticoid exposure was assessed from medical records. The mean of 5 stadiometer measurements of adult height, adjusted for sex and parental height, was analyzed.
  
  
  RESULTS
  One hundred fifty-three patients with asthma (mean age at onset, 6.1 +/- 4.8 years) and 153 age- and sex-matched nonasthmatic subjects were studied. Adult height of patients with asthma (mean age at measurement, 25.7 +/- 5.2 years) was not significantly different from the adult height of non-asthmatic subjects; the overall difference, adjusted for mid-parental height, was -0.20 cm (95% confidence interval from -0.27 to 1.64). The adult height of asthmatic children treated with glucocorticoids was not significantly different from the adult height of patients with asthma not treated with glucocorticoids; the difference after adjusting for mid-parental height was -0.2 cm (95% confidence interval from -0.1 to 0.6).
  
  
  CONCLUSIONS
  We conclude that the attained adult height of patients with asthma is not different from the adult height of age- and sex-matched nonasthmatic subjects and that the attained adult height of asthmatic children treated with glucocorticoids is not significantly different from the adult height of children not treated with glucocorticoids.
authors.affiliation: Division of Area General Internal Medicine, Mayo Clinic, Rochester, Minn, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Silverstein
authors.forename: J W
authors.initials: JW
authors.lastname: Yunginger
authors.forename: C E
authors.initials: CE
authors.lastname: Reed
authors.forename: T
authors.initials: T
authors.lastname: Petterson
authors.forename: D
authors.initials: D
authors.lastname: Zimmerman
authors.forename: J T
authors.initials: JT
authors.lastname: Li
authors.forename: W M
authors.initials: WM
authors.lastname: O'Fallon
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects*; D002648:Child; D015331:Cohort Studies; D016001:Confidence Intervals; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008910:Minnesota; D012189:Retrospective Studies
chemical_list: D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids